Wall Street brokerages predict that Nevro Corp (NYSE:NVRO) will post ($0.66) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Five analysts have made estimates for Nevro’s earnings. The highest EPS estimate is ($0.59) and the lowest is ($0.80). Nevro posted earnings of ($0.59) per share in the same quarter last year, which would suggest a negative year over year growth rate of 11.9%. The firm is expected to issue its next earnings results on Monday, May 6th.
On average, analysts expect that Nevro will report full-year earnings of ($2.31) per share for the current year, with EPS estimates ranging from ($2.48) to ($1.91). For the next fiscal year, analysts anticipate that the business will post earnings of ($1.67) per share, with EPS estimates ranging from ($2.28) to ($1.06). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that follow Nevro.
Nevro (NYSE:NVRO) last issued its quarterly earnings results on Thursday, February 21st. The medical equipment provider reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.15). The company had revenue of $107.90 million during the quarter, compared to the consensus estimate of $107.39 million. Nevro had a negative return on equity of 20.13% and a negative net margin of 12.70%. The firm’s quarterly revenue was up 10.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.15) earnings per share.
NVRO traded down $0.35 during trading on Tuesday, reaching $64.11. The company had a trading volume of 496,982 shares, compared to its average volume of 709,573. The company has a market cap of $2.00 billion, a PE ratio of -39.09 and a beta of 0.21. Nevro has a 52 week low of $34.75 and a 52 week high of $94.34. The company has a quick ratio of 5.64, a current ratio of 7.11 and a debt-to-equity ratio of 0.62.
Several large investors have recently added to or reduced their stakes in the company. Deutsche Bank AG increased its position in shares of Nevro by 24.1% in the fourth quarter. Deutsche Bank AG now owns 307,606 shares of the medical equipment provider’s stock valued at $11,961,000 after buying an additional 59,763 shares in the last quarter. MUFG Securities EMEA plc purchased a new stake in shares of Nevro in the fourth quarter valued at approximately $4,721,000. Geode Capital Management LLC increased its position in shares of Nevro by 9.3% in the fourth quarter. Geode Capital Management LLC now owns 308,995 shares of the medical equipment provider’s stock valued at $12,016,000 after buying an additional 26,356 shares in the last quarter. Norges Bank purchased a new stake in shares of Nevro in the fourth quarter valued at approximately $36,675,000. Finally, HRT Financial LLC increased its position in shares of Nevro by 103.0% in the fourth quarter. HRT Financial LLC now owns 7,416 shares of the medical equipment provider’s stock valued at $288,000 after buying an additional 3,762 shares in the last quarter.
Nevro Company Profile
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Featured Article: Cost of Goods Sold (COGS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.